The hemophilia community is telling FDA that it wants access to post-market safety surveillance data on factor replacement therapies in order to better understand the development of inhibitors, or neutralizing antibodies, that many patients experience.
Patients aired their concerns at a Sept. 22 patient-focused drug development meeting organized by the agency’s Center for Biologics Evaluation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?